**Supplementary Material**

Table of Contents

[Section A. Details of COVAM 3](#_Toc67314437)

[Overview of COVAM 3](#_Toc67314438)

[Supplement Table 1. COVAM parameters specific to regions. 3](#_Toc67314439)

[Section B. Model Validation Results 5](#_Toc67314440)

[Supplement Figure 1. Model validation results. 5](#_Toc67314441)

[Section C. Sensitivity Analyses 7](#_Toc67314442)

[Section C.1 Sensitivity analysis on the drop in adherence to nonpharmaceutical interventions after vaccination 7](#_Toc67314443)

[Supplement Table 2. Controllable spread date and number of cases on December 31, 2021 for different vaccination capacity scenarios when there is no drop in adherence to nonpharmaceutical interventions after vaccination (vaccine effectiveness 90%, vaccine coverage 50%) 7](#_Toc67314444)

[Supplement Table 3. Controllable spread date and number of cases on December 31, 2021 for different vaccination effectiveness scenarios when there is no drop in adherence to nonpharmaceutical interventions after vaccination (vaccine coverage 50%, vaccination capacity 0.01%) 9](#_Toc67314445)

[Supplement Figure 2. Impact of vaccine coverage on the number of confirmed cases in different regions for two different scenarios of adherence to nonpharmaceutical interventions when there is no drop in adherence after vaccination 11](#_Toc67314446)

[Supplement Figure 3. Impact of vaccination and adherence to nonpharmaceutical interventions on the number of cases over time when there is no drop in adherence after vaccination 14](#_Toc67314447)

[Section C.2 Sensitivity analysis on the modeling of vaccination effect 17](#_Toc67314448)

[Supplement Figure 4. Comparison of model predictions to actual NYC data when vaccination effectiveness is modeled as a reduction in probability of becoming infected 17](#_Toc67314449)

[Supplement Table 4: Controllable spread date and number of cases on December 31, 2021 for different daily vaccination capacity scenarios 18](#_Toc67314450)

[Supplement Table 5: Controllable spread date and number of cases on December 31, 2021 for different vaccination effectiveness scenarios when vaccination effectiveness is modeled as a reduction in probability of becoming infected (vaccine coverage 50%, vaccination capacity 0.01%) 19](#_Toc67314451)

[Supplement Figure 5. Impact of vaccine coverage on the number of confirmed cases in different regions for two different scenarios of adherence to nonpharmaceutical interventions when vaccination effectiveness is modeled as a reduction in probability of becoming infected 20](#_Toc67314452)

[Supplement Figure 6. Impact of vaccination and adherence to nonpharmaceutical interventions on the number of cases over time when vaccination effectiveness is modeled as a reduction in probability of becoming infected 21](#_Toc67314453)

# Section A. Details of COVAM

## Overview of COVAM

COVAM is an agent-based simulation model in which agents represent the individuals in a community. Full details of COVAM are published elsewhere1. Key parameters used in COVAM are given in Supplement Table 1.

Supplement Table 1. COVAM parameters specific to regions. (adapted from Alagoz, et al 2020 1)

| Parameter | Value, by region | | | Source |
| --- | --- | --- | --- | --- |
| Dane County | Milwaukee Metro | New York City |
| Population size | 542,364 | 1,576,236 | 8,398,748 | US Census data2 |
| Date of simulation start | March 4th, 2020 | March 4th, 2020 | March 4th, 2020 | -- |
| Number of daily imported exposed agents and dates of importation | 3 daily from Mar 5- 25, 2020; 1 daily onward | 6 daily from Mar 5-25, 2020; 3 daily onward | 160 daily from Mar 5-25, 2020; 32 daily onward | Calibration |
| Number of daily close contacts without social distancing | 10 | 10 | 20 | Calibration and literature3,4 |
| Adherence to social distancing, expressed as percentage drop in number of contacts | Mar 4 - 11, 2020: 0% Mar 12 - 25, 2020: linear increase from 0 - 91% Mar 26 - Apr 30, 2020: 80% May 1 - 13, 2020: 70%  May 14 - June 30, 2020: 60%  July 1 - Aug 31, 2020: 70%  Sep 1 - Nov 8, 2020: 65% Nov 9, 2020 – end of simulation: 70% | Mar 4 – 11, 2020: 0% Mar 12 - 22, 2020: linear increase from 0 - 60% Mar 23 - Apr 7, 2020: 60% Apr 8 - 12, 2020: 80% Apr 13 - May 13, 2020: 70% May 14 - 25, 2020: 60% May 26 - July 15, 2020: 70% July 16 - Aug 14, 2020: 65%  Aug 15 - Sep 29, 2020: 70%  Sep 30 - Oct 29, 2020: 60%  Oct 30 - Nov 8, 2020: 65%  Nov 9, 2020– end of simulation: 70% | Mar 4 - 11, 2020: 0% Mar 12 - 25, 2020: linear increase from 0 - 78% Mar 26 - Apr 17, 2020: 85%  Apr 18 - June 7, 2020: 90%  June 8 - July 1, 2020: 85%  July 2 - Aug 15, 2020: 90%  Aug 16 - Sep 14, 2020: 80%  Sep 15 - Nov 14, 2020: 85%  Nov 15 - Dec 5, 2020: 70%  Dec 6 - Dec 31, 2020: 85%  Jan 1, 2021 – end of simulation: 80% | Cellphone data and calibration5-7 |
| Probability that agent is tested | Mar 4 - Apr 14, 2020: 75% Apr 15 - May 9, 2020: 80% May 10, 2020 - end: 90% | Mar 4 - Apr 14, 2020: 75% Apr 15 - May 9, 2020: 80% May 10, 2020 - end: 90% | Mar 4 - Apr 14, 2020: 75% Apr 15 - May 9, 2020: 80% May 10, 2020 - end: 90% | Literature and calibration8,9 |
| Age distribution (percentage) | 0-19y: 20.8% 20-44y: 46.5% 45-54y: 10.3% 55-64y: 10.2% 65-74y: 7.4% 75-84y: 3.3% 85y+: 1.5% | 0-19y: 28.6% 20-44y: 36.2% 45-54y: 13.7% 55-64y: 8.5% 65-74y: 6.6% 75-84y: 4.7% 85y+: 1.0% | 0-19y: 23.2% 20-44y: 38.6% 45-54y: 13.0% 55-64y: 11.7% 65-74y: 7.1% 75-84y: 3.4% 85y+: 1.9% | US Census data2 |

# Section B. Model Validation Results

In this section, we present the updated results of the validation of COVAM. Model structure and all model inputs for Dane County, Milwaukee metro area, and NYC except vaccination and adherence to NPIs were fixed before July 31, 2020. The structure of the vaccination and vaccination-related inputs were fixed by December 15, 2020. Adherence to social distancing inputs were fixed by January 5, 2021 for Dane County and Milwaukee and by January 14, 2021 for NYC and the predictions of COVAM were compared against the reported number of confirmed cases over time after this date.

In these runs, we used the following settings for the model inputs: vaccination effectiveness is 90%, vaccination coverage is 50%, daily vaccination capacity is 0.1%, drop in adherence after vaccination is 20%, number of imported cases is 1, 3, and 16 for Dane County, Milwaukee, and NYC, respectively, and adherence to NPIs after February 1, 2021 is 70%, 70%, and 85%, for Dane County, Milwaukee, and NYC, respectively. The results in this section use the average values of 100 replications, providing steady estimates around the mean parameter values with small standard errors. Data on case numbers were obtained from the Wisconsin Department of Health Services and the NYC Department of Health.10,11

Supplement Figure 1. Model validation results. In each of the following figures, red dots represent the actual observed cumulative number of confirmed cases, the black solid line represents the model’s predictions, error bars around the black solid line represent 95% confidence intervals for the model’s predictions based on 100 replications, the green dotted line represents the date after which no model input parameter except adherence to NPIs was modified, and the blue dashed line represents the date after which no model input parameter was modified.

(a) Dane County

(b) Milwaukee

(c) NYC

# Section C. Sensitivity Analyses

We conducted a sensitivity analysis on several parameters. In this appendix, we describe these experiments.

## Section C.1 Sensitivity analysis on the drop in adherence to nonpharmaceutical interventions after vaccination

Our base-case assumes that there is a 20% drop in adherence to NPIs among vaccinated individuals regardless of whether they gain immunity or not after vaccination. In this sensitivity analysis, we did all experiments by assuming that there is no drop in adherence to NPIs.

Supplement Table 2. Controllable spread date and number of cases on December 31, 2021 for different vaccination capacity scenarios when there is no drop in adherence to nonpharmaceutical interventions after vaccination (vaccine effectiveness 90%, vaccine coverage 50%). Numbers in parentheses represent percent reduction relative to no vaccine.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dane County | | | | | | | | | | | | | | |
|  | 75% Adherence | | 70% Adherence | | | | 65% Adherence | | | 60% Adherence | | Dynamic Adherence | | |
| Vaccination capacity | Date | Number of cases | Date | | | Number of cases | Date | Number of cases | | Date | Number of cases | Date | Number of cases |
| No Vaccine | 27-Mar-2021 | 43,932 | 18-Jul-2021 | | | 51,784 | 17-Mar-2022 | 111,014 | | 29-Oct-2021 | 200,642 | After June 2022 | 79,285 |
| 0.05% | 22-Mar-2021 | 43,222  (2%) | 25-May-2021 | | | 48,016  (7%) | 20-Oct-2021 | 73,747  (34%) | | 14-Oct-2021 | 150,022  (25%) | 18-Mar-2022 | 72,088  (9%) |
| 0.1% | 18-Mar-2021 | 42,697  (3%) | 2-May-2021 | | | 46,110  (11%) | 4-Aug-2021 | 59,452  (46%) | | 17-Sep-2021 | 109,029  (46%) | 28-Oct-2021 | 64,654  (18%) |
| 0.25% | 12-Mar-2021 | 42,164  (4%) | 1-Apr-2021 | | | 43,374  (16%) | 4-May-2021 | 46,128  (58%) | | 16-Jun-2021 | 53,602  (73%) | 30-May-2021 | 46,579  (41%) |
| 0.5% | 27-Feb-2021 | 40,720  (7%) | 10-Mar-2021 | | | 41,514  (20%) | 26-Mar-2021 | 42,903  (61%) | | 13-Apr-2021 | 45,483  (77%) | 30-Mar-2021 | 42,547  (46%) |
| Milwaukee | | | | | | | | | | | | | | |
|  | 75% Adherence | | | | 70% Adherence | | 65% Adherence | | | 60% Adherence | | Dynamic Adherence | | |
| Vaccination capacity | Date | Number of cases | | Date | | Number of cases | Date | | Number of cases | Date | Number of cases | Date | Number of cases | |
| No Vaccine | 23-Mar-2021 | 167,626 | | 12-Jun-2021 | | 185,343 | 26-Mar-2022 | | 309,809 | 18-Nov-2021 | 567,311 | After June 2022 | 271,692 | |
| 0.05% | 18-Mar-2021 | 165,699  (1%) | | 7-May-2021 | | 177,194  (4%) | 19-Sep-2021 | | 230,229  (26%) | 20-Oct-2021 | 418,533  (26%) | 2-Feb-2022 | 252,269  (7%) | |
| 0.1% | 14-Mar-2021 | 164,239  (2%) | | 21-Apr-2021 | | 172,714  (7%) | 11-Jul-2021 | | 201,894  (35%) | 10-Sep-2021 | 312,232  (45%) | 2-Oct-2021 | 213,120  (22%) | |
| 0.25% | 6-Mar-2021 | 161,330  (4%) | | 27-Mar-2021 | | 165,781  (11%) | 28-Apr-2021 | | 175,693  (43%) | 7-Jun-2021 | 201,573  (64%) | 15-May-2021 | 173,455  (36%) | |
| 0.5% | 26-Feb-2021 | 158,587  (5%) | | 8-Mar-2021 | | 160,720  (13%) | 21-Mar-2021 | | 164,264  (47%) | 7-Apr-2021 | 170,621  (70%) | 26-Mar-2021 | 163,338  (40%) | |
| NYC | | | | | | | | | | | | | | |
|  | 90% Adherence | | | | 85% Adherence | | 80% Adherence | | | 75% Adherence | | Dynamic Adherence | | | |
| Vaccination capacity | Date | Number of cases | | Date | | Number of cases | Date | Number of cases | | Date | Number of cases | Date | Number of cases |
| No Vaccine | 22-Mar-2021 | 699,352 | | 27-Aug-2021 | | 1,110,070 | 4-Sep-2021 | 3,307,090 | | 21-Jun-2021 | 4,999,100 | After June 2022 | 1,308,990 |
| 0.05% | 19-Mar-2021 | 686,290  (2%) | | 28-Jun-2021 | | 987,825  (11%) | 20-Aug-2021 | 2,765,350  (16%) | | 20-Jun-2021 | 4,562,030  (9%) | After June 2022 | 1,274,190  (3%) |
| 0.1% | 17-Mar-2021 | 674,662  (4%) | | 31-May-2021 | | 911,821  (18%) | 3-Aug-2021 | 2,290,640  (31%) | | 19-Jun-2021 | 4,120,280  (18%) | 16-Feb-2022 | 1,193,630  (9%) |
| 0.25% | 11-Mar-2021 | 647,683  (7%) | | 23-Apr-2021 | | 786,153  (29%) | 16-Jun-2021 | 1,394,020  (58%) | | 11-Jun-2021 | 2,843,430  (43%) | 31-Jul-2021 | 865,510  (34%) |
| 0.5% | 4-Mar-2021 | 616,204  (12%) | | 27-Mar-2021 | | 687,376  (38%) | 30-Apr-2021 | 888,980  (73%) | | 6-Jun-2021 | 1,463,240  (71%) | 19-May-2021 | 696,766  (47%) |

Supplement Table 3. Controllable spread date and number of cases on December 31, 2021 for different vaccination effectiveness scenarios when there is no drop in adherence to nonpharmaceutical interventions after vaccination (vaccine coverage 50%, vaccination capacity 0.01%). Numbers in parentheses represent percent reduction in the number of cases relative to no vaccine.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dane County | | | | | | | | | | |
|  | 75% Adherence | | 70% Adherence | | 65% Adherence | | 60% Adherence | | Dynamic Adherence | |
| Vaccine effectiveness | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases |
| No Vaccine | 27-Mar-2021 | 43,932 | 18-Jul-2021 | 51,784 | 17-Mar-2022 | 111,014 | 29-Oct-2021 | 200,642 | After June 2022 | 79,285 |
| 50% | 21-Mar-2021 | 43,178  (2%) | 22-May-2021 | 47,778  (8%) | 16-Oct-2021 | 71,736  (35%) | 20-Oct-2021 | 145,366  (28%) | After June 2022 | 73,250  (8%) |
| 75% | 18-Mar-2021 | 42,884  (2%) | 6-May-2021 | 46,710  (10%) | 25-Aug-2021 | 63,188  (43%) | 3-Oct-2021 | 121,636  (39%) | 15-Feb-2022 | 70,676  (11%) |
| 90% | 18-Mar-2021 | 42,697  (3%) | 2-May-2021 | 46,110  (11%) | 4-Aug-2021 | 59,452  (46%) | 17-Sep-2021 | 109,029  (46%) | 28-Oct-2021 | 64,654  (18%) |
| Milwaukee | | | | | | | | | | |
|  | 75% Adherence | | 70% Adherence | | 65% Adherence | | 60% Adherence | | Dynamic Adherence | |
| Vaccine effectiveness | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases |
| No Vaccine | 23-Mar-2021 | 167,626 | 12-Jun-2021 | 185,343 | 26-Mar-2022 | 309,809 | 18-Nov-2021 | 567,311 | After June 2022 | 271,692 |
| 50% | 18-Mar-2021 | 165,603  (1%) | 5-May-2021 | 176,771  (5%) | 7-Sep-2021 | 226,100  (27%) | 29-Oct-2021 | 405,917  (28%) | After June 2022 | 260,551  (4%) |
| 75% | 16-Mar-2021 | 164,805  (2%) | 25-Apr-2021 | 174,158  (6%) | 29-Jul-2021 | 209,451  (32%) | 1-Oct-2021 | 343,125  (40%) | 24-Dec-2021 | 232,820  (14%) |
| 90% | 14-Mar-2021 | 164,239  (2%) | 21-Apr-2021 | 172,714  (7%) | 11-Jul-2021 | 201,894  (35%) | 10-Sep-2021 | 312,232  (45%) | 2-Oct-2021 | 213,120  (22%) |
| NYC | | | | | | | | | | |
|  | 90% Adherence | | 85% Adherence | | 80% Adherence | | 75% Adherence | | Dynamic Adherence | |
| Vaccine effectiveness | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases |
| No Vaccine | 22-Mar-2021 | 699,352 | 27-Aug-2021 | 1,110,070 | 4-Sep-2021 | 3,307,090 | 21-Jun-2021 | 4,999,100 | After June 2022 | 1,308,990 |
| 50% | 19-Mar-2021 | 685,428  (2%) | 25-Jun-2021 | 979,607  (12%) | 19-Aug-2021 | 2,711,210  (18%) | 20-Jun-2021 | 4,514,110  (10%) | After June 2022 | 1,272,390  (3%) |
| 75% | 17-Mar-2021 | 678,957  (3%) | 6-Jun-2021 | 936,081  (16%) | 11-Aug-2021 | 2,444,070  (26%) | 19-Jun-2021 | 4,269,560  (15%) | After June 2022 | 1,256,520  (4%) |
| 90% | 17-Mar-2021 | 674,662  (4%) | 31-May-2021 | 911,821  (18%) | 3-Aug-2021 | 2,290,640  (31%) | 19-Jun-2021 | 4,120,280  (18%) | 16-Feb-2022 | 1,193,630  (9%) |

Supplement Figure 2. Impact of vaccine coverage on the number of confirmed cases in different regions for two different scenarios of adherence to nonpharmaceutical interventions when there is no drop in adherence after vaccination. In this figure, we assumed that vaccine effectiveness is equal to 90%, vaccine capacity is 0.1%/day.

a. Dane, adherence to NPIs is fixed at a level of 70%

b. Dane, adherence to NPIs is dynamic

c. Milwaukee, adherence to NPIs is fixed at a level of 70%

d. Milwaukee, adherence to NPIs is dynamic

e. NYC, adherence to NPIs is fixed at a level of 85%

f. NYC, adherence to NPIs is dynamic

Supplement Figure 3. Impact of vaccination and adherence to nonpharmaceutical interventions on the number of cases over time when there is no drop in adherence after vaccination. In these experiments, we assumed that vaccine effectiveness is 90%, vaccine coverage is 50%, and daily vaccination capacity is 0.1% for the vaccination scenario.

a. Dane, vaccination

b. Dane, No vaccination

c. Milwaukee, vaccination

d. Milwaukee, no vaccination

e. NYC, vaccination

f. NYC, no vaccination

## Section C.2 Sensitivity analysis on the modeling of vaccination effect

COVAM assumes that the vaccination is effective by simply making a proportion of the vaccinated individuals becoming immune to SARS-CoV-2 therefore do not become contagious and therefore do not spread the virus to others. For example, 90% effectiveness implies that 9 out of 10 individuals become immune and 1 out of 10 remains susceptible. An alternative way of modeling effectiveness is to assume that vaccine does not eliminate the risk of infection for vaccinated individuals but reduces the probability of these individuals becoming infected by contagious individuals. In this alternative scenario, vaccinated individuals do not become completely immune, instead, their risk of being infected is reduced by 90%. Again, we conducted this experiment only for NYC. We did not change any parameters except this structural implementation.

Below, we first present the results of the validation, which show that COVAM was able to replicate the observed cumulative number of COVID-19 cases using the new set of values for adherence to NPIs. We then present the results of our experiments.

## Supplement Figure 4. Comparison of model predictions to actual NYC data when vaccination effectiveness is modeled as a reduction in probability of becoming infected

Supplement Table 4: Controllable spread date and number of cases on December 31, 2021 for different daily vaccination capacity scenarios when vaccination effectiveness is modeled as a reduction in probability of becoming infected (vaccine effectiveness 90%, vaccine coverage 50%). Numbers in parentheses represent percent reduction relative to no vaccine.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| NYC | | | | | | | | | | | | |
|  | 90% Adherence | | | 85% Adherence | | 80% Adherence | | 75% Adherence | | Dynamic Adherence | | | |
| Vaccination capacity | Date | Number of cases | Date | | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases |
| No Vaccine | 22-Mar-2021 | 699,352 | 27-Aug-2021 | | 1,110,070 | 4-Sep-2021 | 3,307,090 | 21-Jun-2021 | 4,999,100 | After June 2022 | 1,308,990 |
| 0.05% | 20-Mar-2021 | 686,086  (2%) | 25-Jun-2021 | | 986,528  (11%) | 20-Aug-2021 | 2,764,620  (16%) | 21-Jun-2021 | 4,570,160  (9%) | After June 2022 | 1,273,190  (3%) |
| 0.1% | 17-Mar-2021 | 674,462  (4%) | 30-May-2021 | | 909,986  (18%) | 3-Aug-2021 | 2,287,610  (31%) | 19-Jun-2021 | 4,132,220  (17%) | 9-Feb-2022 | 1,193,500  (9%) |
| 0.25% | 11-Mar-2021 | 647,315  (7%) | 23-Apr-2021 | | 784,676  (29%) | 15-Jun-2021 | 1,385,800  (58%) | 11-Jun-2021 | 2,839,570  (43%) | 28-Jul-2021 | 873,254  (33%) |
| 0.5% | 3-Mar-2021 | 615,607  (12%) | 26-Mar-2021 | | 685,706  (38%) | 28-Apr-2021 | 882,795  (73%) | 5-Jun-2021 | 1,439,030  (71%) | 13-May-2021 | 689,698  (47%) |

Supplement Table 5: Controllable spread date and number of cases on December 31, 2021 for different vaccination effectiveness scenarios when vaccination effectiveness is modeled as a reduction in probability of becoming infected (vaccine coverage 50%, vaccination capacity 0.01%). Numbers in parentheses represent percent reduction relative to no vaccine.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| NYC | | | | | | | | | | |
|  | 90% Adherence | | 85% Adherence | | 80% Adherence | | 75% Adherence | | Dynamic Adherence | |
| Vaccine effectiveness | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases | Date | Number of cases |
| No Vaccine | 22-Mar-2021 | 699,352 | 27-Aug-2021 | 1,110,070 | 4-Sep-2021 | 3,307,090 | 21-Jun-2021 | 4,999,100 | After June 2022 | 1,308,990 |
| 50% | 18-Mar-2021 | 683,968  (2%) | 18-Jun-2021 | 966,379  (13%) | 20-Aug-2021 | 2,670,380  (19%) | 21-Jun-2021 | 4,519,590  (10%) | After June 2022 | 1,276,990  (2%) |
| 75% | 17-Mar-2021 | 678,460  (3%) | 6-Jun-2021 | 930,525  (16%) | 10-Aug-2021 | 2,430,490  (27%) | 20-Jun-2021 | 4,288,620  (14%) | After June 2022 | 1,257,190  (4%) |
| 90% | 17-Mar-2021 | 674,462  (4%) | 30-May-2021 | 909,986  (18%) | 3-Aug-2021 | 2,287,610  (31%) | 19-Jun-2021 | 4,132,220  (17%) | 9-Feb-2022 | 1,193,500  (9%) |

Supplement Figure 5. Impact of vaccine coverage on the number of confirmed cases in different regions for two different scenarios of adherence to nonpharmaceutical interventions when vaccination effectiveness is modeled as a reduction in probability of becoming infected. In this figure, we assumed that vaccine effectiveness is equal to 90%, vaccine capacity is 0.1%/day.

a. NYC, adherence to NPIs is fixed at a level of 85%

b. NYC, adherence to NPIs is dynamic

Supplement Figure 6. Impact of vaccination and adherence to nonpharmaceutical interventions on the number of cases over time when vaccination effectiveness is modeled as a reduction in probability of becoming infected. In these experiments, we assumed that vaccine effectiveness is 90%, vaccine coverage is 50%, and daily vaccination capacity is 0.1% for the vaccination scenario.

a. NYC, vaccination

b. NYC, no vaccination

**Supplement References**

1. Alagoz O, Sethi AK, Patterson BW, Churpek M, Safdar N. Effect of Timing of and Adherence to Social Distancing Measures on COVID-19 Burden in the United States: A Simulation Modeling Approach. *Annals of internal medicine.* 2020.

2. United States Census Bureau. Age and Sex Table. 2020; <https://data.census.gov/cedsci/>. Accessed August 18, 2020.

3. Del Valle SY, Hyman JM, Hethcote HW, Eubank SG. Mixing patterns between age groups in social networks. *Social Networks.* 2007;29(4):539-554.

4. Lee BY, Brown ST, Cooley P, et al. Simulating school closure strategies to mitigate an influenza epidemic. *Journal of Public Health Management and Practice.* 2010;16(3):252-261.

5. GeoDS Lab @ UW-Madison. Mapping Mobility Changes in Response to COVID-19. 2021; <https://geods.geography.wisc.edu/covid19/physical-distancing/>. Accessed February 1, 2021.

6. Google. COVID-19 Community Mobility Report. 2021; <https://www.google.com/covid19/mobility/>. Accessed February 1, 2021.

7. Unacast. Social Distancing Scoreboard. 2021; <https://www.unacast.com/covid19/social-distancing-scoreboard>. Accessed February 1, 2021.

8. Crisanti A, Cassone A. In one Italian town, we showed mass testing could eradicate the coronavirus. *The Guardian.* March 20, 2020, 2020: <https://www.theguardian.com/commentisfree/2020/mar/2020/eradicated-coronavirus-mass-testing-covid-2019-italy-vo>.

9. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences.* 2020;63(5):706-711.

10. New York City Department of Health. COVID-19: Data. 2021; <https://www1.nyc.gov/site/doh/covid/covid-19-data.page>. Accessed February 1, 2021.

11. Wisconsin Department of Health Services. COVID-19: Wisconsin Data. 2021; <https://www.dhs.wisconsin.gov/covid-19/data.htm>. Accessed February 1, 2021.